Navigation Links
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:11/30/2007

>

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... dense, urban centers around the world, many people live ... tall buildings that block sunlight. And as the global ... together, the darkness will only spread. , To ... translucent panel that redirects sunlight onto narrow streets and ... over the edge at an angle, where it spreads ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... for high-risk bladder cancer, chemotherapy before or after ... practice. The findings are published early online in ... American Cancer Society. , Clinical trials have shown ... bladder cancer who are given chemotherapy before surgery. ... surgery also improves survival. To investigate the use ...
(Date:4/11/2014)... control brain cell production could pave the way for ... Scientists have gained new understanding of the role played ... nerve and brain cells are formed a process ... healthy. Their findings could help explain what happens when ... fundamental characteristic of many diseases including cancer. , ...
Breaking Medicine News(10 mins):Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... cancer, new research finds. Prior research has shown higher ... this study is among the first to show that lower ... as gastrointestinal bleeding -- may also be effective, said Eric ...
... of fertilizer that feeds breast cancer progression, significantly ... researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... the immune cells that are trying to fight ... the body against disease into aiders and abettors. ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... Wednesday over whether the diet drug Meridia should be pulled ... risk of heart attack and stroke. Members of an ... said the drug should remain available to consumers called for ...
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Children with ... that is, yawn in response to seeing others yawn, a ... contagion," an unconscious response that reflects a recognition of how ... and others is an important step in a child,s social ...
... WEDNESDAY, Sept. 15 (HealthDay News) -- When people with chronic ... the level of hemoglobin cells in their blood should go ... levels don,t increase by much, these "poor responders" experience a ... Reporting in the Sept. 16 issue of the New ...
... Center at the University of California, San Diego has ... the American College of Radiology (ACR). ... and this prestigious certificate recognizes our extraordinary effort," said ... Moores UCSD Cancer Center. "ACR leads the way toward ...
Cached Medicine News:Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 2Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 3Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 2Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 3Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 2Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 3
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... , RIDGEFIELD, Conn., Aug. 25 Results of ... Warfarin, Compared to Dabigatran)(1) study will be presented at the ... Aug. 30. The primary objective of RE-LY was to ... thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, ...
... August 25 20% of parents seek medical,help because ... baby,and the accompanying discomfort (crying). Reputed medical journal "Archives,of ... recently,published the results of the clinical research project that ... department of the Brussels,University Hospital. , ...
Cached Medicine Technology:Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7Medical World Recognises New Therapy for Reflux Babies 2
... FloSeal is a prorietary combination of ... FloSeal is a high viscosity gel for ... capillary oozing to arterial spurting. FloSeal is ... to haemostasis when control of bleeding by ...
... gives you new options for skin wound ... application only to hold closed easily approximated ... including punctures from minimally invasive surgery, and ... may be used in conjunction with, but ...
... Indermil® tissue adhesive is indicated for the ... incisions, and trauma-induced lacerations in areas of ... and have easily approximated skin edges. In ... adhesive may act as a barrier to ...
... office to eliminate paper completely without ... functions. With PT Medical's digital ... add digital signatures to informed consents, ... that require a patient, doctor, or ...
Medicine Products: